{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T17:12:06Z","timestamp":1781889126085,"version":"3.54.5"},"reference-count":29,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Wroclaw Medical University","award":["Subz. C140. 24.082"],"award-info":[{"award-number":["Subz. C140. 24.082"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CIMB"],"abstract":"<jats:p>Myelodysplastic neoplasms (MDS) represent a heterogeneous group of neoplastic bone marrow disorders. A crucial component in regulating bone marrow cell apoptosis is the B-cell CLL\/lymphoma 2 (BCL-2) protein. This retrospective study aimed to assess BCL-2 expression by immunohistochemistry in trephine biopsy specimens from 76 patients diagnosed with MDS. The obtained retrospective results were correlated with clinical parameters, including age, sex, MDS subtype, IPSS, IPSS-R, bone marrow blast percentage, Ogata score, response to treatment, blood morphology parameters, and overall survival (OS). The median follow-up duration was 16 months. During the observation period, 58 patients died (median OS of this group: 14.6 months), and 25 patients experienced progression to acute myeloid leukemia. The median BCL-2 expression assessed using the Histoscore (H-score) was 10. Patients with BCL-2 expression below 10 had better survival outcomes than those with expression \u2265 10. Furthermore, patients without detectable BCL-2 expression had significantly better survival compared to those with detectable BCL-2 expression (p = 0.0084). Higher BCL-2 expression was significantly associated with high and very high cytogenetic risk, as defined by IPSS-R. BCL-2 immunohistochemistry should be viewed as a complementary biomarker that, when integrated with IPSS-R and mutational data, could refine therapeutic algorithms.<\/jats:p>","DOI":"10.3390\/cimb47050346","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T09:13:38Z","timestamp":1747041218000},"page":"346","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Role of BCL-2 Expression in Patients with Myelodysplastic Neoplasms"],"prefix":"10.3390","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8036-073X","authenticated-orcid":false,"given":"Bart\u0142omiej","family":"Kuszczak","sequence":"first","affiliation":[{"name":"Department and Clinic of Hematology, Cellular Therapies and Internal Medicine, Medical University of Wroc\u0142aw, 50-367 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Zduniak","sequence":"additional","affiliation":[{"name":"Department of Pathology, Lower Silesian Center of Oncology Pulmonology and Hematology, 53-439 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Jendzierowska","sequence":"additional","affiliation":[{"name":"Department and Clinic of Hematology, Cellular Therapies and Internal Medicine, Medical University of Wroc\u0142aw, 50-367 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Wr\u00f3bel","sequence":"additional","affiliation":[{"name":"Department and Clinic of Hematology, Cellular Therapies and Internal Medicine, Medical University of Wroc\u0142aw, 50-367 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Zi\u00f3\u0142kowski","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Pathology, Faculty of Medicine, Medical University of Wroc\u0142aw, 50-367 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Rybka","sequence":"additional","affiliation":[{"name":"Department and Clinic of Hematology, Cellular Therapies and Internal Medicine, Medical University of Wroc\u0142aw, 50-367 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41572-022-00402-5","article-title":"Myelodysplastic Syndromes","volume":"8","author":"Li","year":"2022","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.blre.2018.09.001","article-title":"Epidemiology of Myelodysplastic Syndromes: Why Characterizing the Beast Is a Prerequisite to Taming It","volume":"34","author":"Zeidan","year":"2019","journal-title":"Blood Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1056\/NEJMra0902908","article-title":"Mechanisms of Disease. Myelodysplastic Syndromes","volume":"361","author":"Tefferi","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.leukres.2011.06.001","article-title":"Incidence and Prevalence of Myelodysplastic Syndromes: Data from the D\u00fcsseldorf MDS-Registry","volume":"35","author":"Neukirchen","year":"2011","journal-title":"Leuk. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrclinonc.2017.197","article-title":"The Bone-Marrow Niche in MDS and MGUS: Implications for AML and MM","volume":"15","author":"Ghobrial","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Graf, J.R., Forster, S., Bruehl, F.K., Banz, Y., Hallal, M., Brodard, J., Bacher, V.U., Allam, R., Sch\u00fcrch, C.M., and Bonadies, N. (2021). Diagnostic and Prognostic Implications of Caspase-1 and Pd-l1 Co-expression Patterns in Myelodysplastic Syndromes. Cancers, 13.","DOI":"10.3390\/cancers13225712"},{"key":"ref_7","first-page":"288","article-title":"Deregulacja Rodziny Bia\u0142ek BCL2 w Ch\u0142oniakach B-Kom\u00f3rkowych\u2014Implikacje Molekularne, Patogenetyczne, Kliniczne i Terapeutyczne Deregulation of BCL2 Family Proteins in B-Cell Lymphomas\u2014Molecular, Pathogenetic, Clinical and Therapeutic Implications","volume":"3","author":"Kliszek","year":"2012","journal-title":"Hematologia"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Campbell, K.J., and Tait, S.W.G. (2018). Targeting BCL-2 Regulated Apoptosis in Cancer. Open Biol., 8.","DOI":"10.1098\/rsob.180002"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0145-2126(98)00051-4","article-title":"Bcl-2 Expression by Myeloid Precursors in Myelodysplastic Syndromes: Relation to Disease Progression","volume":"22","author":"Davis","year":"1998","journal-title":"Leuk. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.leukres.2010.05.023","article-title":"The Lower Risk MDS Patient at Risk of Rapid Progression","volume":"34","author":"Mittelman","year":"2010","journal-title":"Leuk. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ajh.26771","article-title":"A Phase 1b Study of Venetoclax and Azacitidine Combination in Patients with Relapsed or Refractory Myelodysplastic Syndromes","volume":"98","author":"Zeidan","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1182\/bloodadvances.2021005566","article-title":"Adding Venetoclax to Fludarabine\/Busulfan RIC Transplant for High-Risk MDS and AML Is Feasible, Safe, and Active","volume":"5","author":"Garcia","year":"2021","journal-title":"Blood Adv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1182\/blood-2019-124437","article-title":"A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Na\u00efve Patients with Higher-Risk Myelodysplastic Syndrome","volume":"134","author":"Wei","year":"2019","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.annonc.2020.11.002","article-title":"Myelodysplastic Syndromes: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up\u2020\u2606","volume":"32","author":"Fenaux","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/ajh.10108","article-title":"Expression and Prognostic Significance of Bcl-2 Family Proteins in Myelodysplastic Syndromes","volume":"70","author":"Boudard","year":"2002","journal-title":"Am. J. Hematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000040984","article-title":"Apoptosis, Bcl-2 Expression and P53 Accumulation in Myelodysplastic Syndrome, Myelodysplastic-Syndrome-Derived Acute Myelogenous Leukemia and de Novo Acute Myelogenous Leukemia","volume":"102","author":"Kurotaki","year":"1999","journal-title":"Acta Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood.V96.12.3932","article-title":"The Role of Apoptosis, Proliferation, and the Bcl-2-Related Proteins in the Myelodysplastic Syndromes and Acute Myeloid Leukemia Secondary to MDS","volume":"96","author":"Parker","year":"2000","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0301-472X(02)01078-0","article-title":"The Role of Mitochondrial-Mediated Apoptosis in a Myelodysplastic Syndrome Secondary to Congenital Deletion of the Short Arm of Chromosome 4","volume":"31","author":"Dror","year":"2003","journal-title":"Exp. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e756","DOI":"10.1016\/S2352-3026(22)00216-2","article-title":"Azacitidine plus Venetoclax in Patients with High-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukaemia: Phase 1 Results of a Single-Centre, Dose-Escalation, Dose-Expansion, Phase 1\u20132 Study","volume":"9","author":"Bazinet","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2198098","DOI":"10.1080\/16078454.2023.2198098","article-title":"The Efficacy and Safety of Venetoclax and Azacytidine Combination Treatment in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome: Systematic Review and Meta-Analysis","volume":"28","author":"Du","year":"2023","journal-title":"Hematology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41591-022-01696-4","article-title":"Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy","volume":"28","author":"Yang","year":"2022","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1002\/ijc.34377","article-title":"Role of BCL-2 inhibition in myelodysplastic syndromes","volume":"152","author":"Blum","year":"2023","journal-title":"Int. J. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"101521","DOI":"10.1016\/j.beha.2023.101521","article-title":"Mechanisms of resistance to hypomethylating agents and BCL-2 inhibitors","volume":"36","author":"Desai","year":"2023","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Kuszczak, B., Wr\u00f3bel, T., Wicherska-Paw\u0142owska, K., and Rybka, J. (2023). The Role of BCL-2 and PD-1\/PD-L1 Pathway in Pathogenesis of Myelodysplastic Syndromes. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054708"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Kok, C.H., Yeung, D.T., and Hiwase, D.K. (2024). Special Issue \u201cAdvances in Molecular Pathogenesis and Targeted Therapies for Myeloid Neoplasms\u201d. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25042056"},{"key":"ref_27","first-page":"66","article-title":"BCL-2 family proteins in myelodysplastic syndromes: From pathogenesis to targeted therapy","volume":"59","author":"Marchica","year":"2022","journal-title":"Semin. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1182\/blood-2019-124994","article-title":"A phase 1b study of venetoclax and azacitidine in patients with relapsed\/refractory myelodysplastic syndrome","volume":"134","author":"Zeidan","year":"2019","journal-title":"Blood"},{"key":"ref_29","first-page":"521","article-title":"Novel treatment strategies of targeting BCL-2, BCL-XL and MCL-1","volume":"52","author":"Kusumoto","year":"2022","journal-title":"Jpn. J. Clin. Oncol."}],"container-title":["Current Issues in Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1467-3045\/47\/5\/346\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:30:36Z","timestamp":1760031036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1467-3045\/47\/5\/346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,10]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["cimb47050346"],"URL":"https:\/\/doi.org\/10.3390\/cimb47050346","relation":{},"ISSN":["1467-3045"],"issn-type":[{"value":"1467-3045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,10]]}}}